scholarly journals Emerging Therapies for the Treatment of Central Retinal Vein Occlusion and Macular Edema

2019 ◽  
pp. 54-57
Keyword(s):  
Macular Edema ◽  
Laser Treatment ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Current Treatment ◽  
Vein Occlusion ◽  
Anti Vegf ◽  
Emerging Therapies ◽  
New Applications ◽  
Central Retinal Vein

Many agents are used in the current treatment of central retinal vein occlusion and its complications. These treatments include anti-VEGF agents and steroids. Laser treatment is still up to date. In addition, many treatments are being developed outside the routine are being studied. In this review, treatments and new applications other than anti-VEGF, steroids, and laser used in the treatment of central retinal vein occlusion and macular edema will be reviewed.

scholarly journals The Effect of Antivascular Endothelial Growth Factor Therapy on the Development of Neovascular Glaucoma after Central Retinal Vein Occlusion: A Retrospective Analysis

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Christina L. Ryu ◽  
Adrian Elfersy ◽  
Uday Desai ◽  
Thomas Hessburg ◽  
Paul Edwards ◽  
...  
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Significant Risk ◽  
Case Series ◽  
Neovascular Glaucoma ◽  
Vein Occlusion ◽  
Anti Vegf ◽  
Central Retinal Vein

Purpose. Ischemic central retinal vein occlusion (CRVO) eyes are at high risk of developing neovascular glaucoma (NVG). Our purpose is to investigate the effect of anti-VEGF therapy for macular edema after CRVO on the development of neovascular glaucoma (NVG) in ischemic CRVO eyes.Methods. This is a retrospective case series of 44 eyes from 44 patients with CRVO treated with anti-VEGF therapy for macular edema. The primary outcome was the development of NVG.Results. Of the 44 eyes, 14 eyes had ischemic CRVO, and 30 eyes had nonischemic CRVO. Nonischemic eyes received a mean of 8.4 anti-VEGF doses, over mean follow-up of 24 months. One nonischemic eye (3.3%) developed NVD but not NVG. The 14 ischemic eyes received a mean of 5.6 anti-VEGF doses, with mean follow-up of 23 months. Of these 14 ischemic eyes, two eyes (14%) developed iris neovascularization and 3 eyes (21%) developed posterior neovascularization. Three of these 5 eyes with neovascularization progressed to NVG, at 19.7 months after symptom onset, on average.Conclusion. Anti-VEGF therapy for macular edema may delay, but does not prevent, the development of ocular NV in ischemic CRVO. Significant risk of NVG still exists for ischemic CRVO eyes.

Predictors of Short-Term Visual Outcome after Anti-VEGF Therapy of Macular Edema due to Central Retinal Vein Occlusion

2011 ◽  
Vol 52 (6) ◽  
pp. 3334 ◽  
Author(s):  
Ute E. K. Wolf-Schnurrbusch ◽  
Ramzi Ghanem ◽  
Simon P. Rothenbuehler ◽  
Volker Enzmann ◽  
Carsten Framme ◽  
...  
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Visual Outcome ◽  
Short Term ◽  
Vein Occlusion ◽  
Anti Vegf ◽  
Central Retinal Vein

Intravitreal Ranibizumab Treatment in Macular Edema Secondary to Central Retinal Vein Occlusion

2019 ◽  
pp. 26-28
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Current Treatment ◽  
Intravitreal Ranibizumab ◽  
Vascular Growth ◽  
Vein Occlusion ◽  
Vascular Growth Factor ◽  
Central Retinal Vein ◽  
Ranibizumab Treatment

The two main complications of central retinal vein occlusion are macular edema and neovascularizations. Intravitreal anti-vascular growth factor and corticosteroid injections are the mainstays of the current treatment of central retinal vein occlusion. In this review, we aimed to summarize the clinical studies of intravitreal ranibizumab in macular edema secondary to central retinal vein occlusion.

scholarly journals Intravitreal Ranibizumab Treatment in Macular Edema Secondary to Central Retinal Vein Occlusion

2019 ◽  
pp. 26-28
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Current Treatment ◽  
Intravitreal Ranibizumab ◽  
Vascular Growth ◽  
Vein Occlusion ◽  
Vascular Growth Factor ◽  
Central Retinal Vein ◽  
Ranibizumab Treatment

The two main complications of central retinal vein occlusion are macular edema and neovascularizations. Intravitreal anti-vascular growth factor and corticosteroid injections are the mainstays of the current treatment of central retinal vein occlusion. In this review, we aimed to summarize the clinical studies of intravitreal ranibizumab in macular edema secondary to central retinal vein occlusion.

scholarly journals Central Retinal Vein Occlusion in 2 Patients Using Antipsychotic Drugs

2017 ◽  
Vol 8 (2) ◽  
pp. 410-415 ◽  
Author(s):  
Koichiro Taki ◽  
Teruyo Kida ◽  
Masanori Fukumoto ◽  
Takaki Sato ◽  
Hidehiro Oku ◽  
...  
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Antipsychotic Drugs ◽  
Antipsychotic Medications ◽  
Case Presentation ◽  
Cotton Wool Spots ◽  
Vein Occlusion ◽  
Anti Vegf ◽  
Central Retinal Vein

Purpose: To report our findings in 2 patients who developed a central retinal vein occlusion (CRVO) and were chronic users of antipsychotic medications. Case Presentation: Case 1 was a 62-year-old woman who had a sudden reduction of vision in her right eye to 20/2,000. Her fundus showed signs of an impending CRVO with marked macular edema. She had been taking antipsychotic drugs (quetiapine fumarate and risperidone) for about 2 years. She refused anti-VEGF therapy for her macular edema but selected systemic kallidinogenase. Two days later, the macular edema was significantly reduced but the number of cotton wool spots (CWS) was increased. Ten days later, the macular edema was resolved and her BCVA improved to 20/60. The CWS gradually disappeared, and her BCVA improved to 20/20. Case 2 was a 43-year-old man who presented with vision reduction in his right eye of 1 week’s duration. His BCVA was 20/50 and his fundus showed signs of a CRVO-related macular edema with CWS in the peripapillary area. He had been taking sulpiride (DogmatylTM) for depression for 1 year, and his blood test showed an increase in red blood cells and hematocrit. Anti-VEGF therapy was performed, and the macular edema was resolved with vision improving to 20/20. There has been no recurrence to date in both cases. Conclusions: These results indicate that a CRVO can be a complication of chronic use of antipsychotic medications. However, early treatment can lead to good outcomes. Clinicians should question patients who develop a sudden CRVO whether they are using antipsychotic medications.

scholarly journals Cytokines and Pathogenesis of Central Retinal Vein Occlusion

2020 ◽  
Vol 9 (11) ◽  
pp. 3457
Author(s):  
Hidetaka Noma ◽  
Kanako Yasuda ◽  
Masahiko Shimura
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Vision Loss ◽  
Neovascular Glaucoma ◽  
Retinal Blood Flow ◽  
Vein Occlusion ◽  
Anti Vegf ◽  
Central Retinal Vein

Central retinal vein occlusion (CRVO) causes macular edema and subsequent vision loss and is common in people with diseases such as arteriosclerosis and hypertension. Various treatments for CRVO-associated macular edema have been trialed, including laser photocoagulation, with unsatisfactory results. However, when the important pathogenic role of vascular endothelial growth factor (VEGF) in macular edema was identified, the treatment of CRVO was revolutionized by anti-VEGF therapy. However, despite the success of intraocular injection of anti-VEGF agents in many patients with CRVO, some patients continue to suffer from refractory or recurring edema. In addition, the expression of inflammatory cytokines increases over time, causing more severe inflammation and a condition that is increasingly resistant to anti-VEGF therapy. This indicates that the pathogenesis of macular edema in CRVO is more complex than originally thought and may involve factors or cytokines associated with inflammation and ischemia other than VEGF. CRVO is also associated with leukocyte abnormalities and a gradual reduction in retinal blood flow velocity, which increase the likelihood of it developing from the nonischemic type into the more severe ischemic type; in turn, this results in excessive VEGF expression and subsequent neovascular glaucoma. Here, we review the role of different factors and cytokines involved in CRVO pathogenesis and propose a mechanism that holds promise for the development of novel therapies.

scholarly journals Intravitreal Ranibizumab Treatment in Macular Edema Secondary to Central Retinal Vein Occlusion

2019 ◽  
pp. 26-28
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Current Treatment ◽  
Intravitreal Ranibizumab ◽  
Vascular Growth ◽  
Vein Occlusion ◽  
Vascular Growth Factor ◽  
Central Retinal Vein ◽  
Ranibizumab Treatment

The two main complications of central retinal vein occlusion are macular edema and neovascularizations. Intravitreal anti-vascular growth factor and corticosteroid injections are the mainstays of the current treatment of central retinal vein occlusion. In this review, we aimed to summarize the clinical studies of intravitreal ranibizumab in macular edema secondary to central retinal vein occlusion.

Sign in / Sign up

Export Citation Format

Share Document